Saad Z. Usmani, MD, MBA, FACP, Details the Safety Profile for CARTITUDE-1 Trial

Video

Usmani discussed the common adverse events observed from CARTITUDE-1, including hematologic events and cytokine release syndrome.

CancerNetwork® sat down with Saad Z. Usmani, MD, MBA, FACP, of the Levine Cancer Institute in Charlotte, North Carolina, at the 2021 American Society of Clinical Oncology (ASCO) Annual Meeting, to discuss the safety profile of the phase 1b/2 CARTITUDE-1 trial that looked at patients with relapsed/refractory multiple myeloma treated with ciltacabtagene autoleucel (cilta-cel).

Transcription:

For CARTITUDE-1, there were no new safety updates because the more common adverse events that we observe with CAR T-cell therapies—not just with the previously reported [B-cell maturation antigen]–directed CAR T-cells, but also with CD19 CAR T-cells—[are] hematologic AEs. Those were quite common and consistent with what has been reported in the past. The same is true for [cytokine release syndrome (CRS)]. Ninety-two patients out of the 97 had CRS, but most of those were grade 1 or grade 2, and CRS resolved in 99% of the patients within 14 days of onset.

Reference

Usmani SZ, Berdeja JG, Madduri D, et al. Ciltacabtagene autoleucel, a B-cell maturation antigen (BCMA)-directed chimeric antigen receptor T-cell (CAR-T) therapy, in relapsed/refractory multiple myeloma (R/R MM): Updated results from CARTITUDE-1. J Clin Oncol. 2021,39(suppl 15):8005. doi:10.1200/JCO.2021.39.15_suppl.8005

Newsletter

Stay up to date on recent advances in the multidisciplinary approach to cancer.

Recent Videos
Success with the 177Lu-PSMA-617 radioligand therapy would be transformative for the clear cell renal cell carcinoma treatment landscape.
An ongoing phase 1 trial seeks to prove XmAb819 as an effective treatment and ENPP3 as a plausible target in patients with relapsed or refractory RCC.
“The therapy is designed to prevent both CAR T-cell inactivation and to restore the anti-tumor immunity of the white blood cells that have gotten through the tumor,” said Marasco, MD, PhD.
Ongoing studies aim to combine base immunotherapy regimens with novel agents to potentially improve outcomes among patients with kidney cancer.
Investigators have found a way to reduce liver and biliary toxicity when targeting the molecule CAIX in patients with clear cell renal cell carcinoma.
Neoantigen-targeting vaccines resulted in an absence of recurrence in 9 patients with high-risk kidney cancer, according to David A. Braun, MD, PhD.
The Kidney Cancer Research Consortium may allow collaborators to form more mechanistic and scientifically driven efforts in the field.
Wayne A. Marasco, MD, PhD, stated that by targeting 2 molecules instead of 1, higher levels of tumor cell killing can be achieved in patients with clear cell renal cell carcinoma.
Leading experts in the breast cancer field highlight the use of CDK4/6 inhibitors, antibody-drug conjugates, and other treatment modalities.
Related Content